Item type |
デフォルトアイテムタイプ_(フル)(1) |
公開日 |
2023-03-18 |
タイトル |
|
|
タイトル |
Results of a preliminary study using hypofractionated involved-field radiation therapy and concurrent carboplatin/paclitaxel in the treatment of locally advanced non-small-cell lung cancer |
|
言語 |
en |
作成者 |
Matsuura, Kanji
Kimura, Tomoki
Kashiwado, Kozo
Fujita, Kazushi
Akagi, Yukio
Yuki, Shintarou
Murakami, Yuji
Wadasaki, Koichi
Monzen, Yoshio
Ito, Atsushi
Kagemoto, Masayuki
Mori, Masaki
Ito, Katsuhide
Nagata, Yasushi
|
アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
権利情報 |
|
|
権利情報 |
Copyright (c) 2009 Springer |
主題 |
|
|
主題Scheme |
Other |
|
主題 |
Involved-field radiation therapy (IFRT) |
主題 |
|
|
主題Scheme |
Other |
|
主題 |
Elective nodal irradiation (ENI) |
主題 |
|
|
主題Scheme |
Other |
|
主題 |
Three-dimensional conformal radiation therapy (3DCRT) |
主題 |
|
|
主題Scheme |
Other |
|
主題 |
Non-small-cell lung cancer (NSCLC) |
主題 |
|
|
主題Scheme |
Other |
|
主題 |
Carboplatin (CBDCA) |
主題 |
|
|
主題Scheme |
Other |
|
主題 |
Paclitaxel (PTX) |
主題 |
|
|
主題Scheme |
NDC |
|
主題 |
490 |
内容記述 |
|
|
内容記述 |
We aimed to evaluate the feasibility and efficacy of hypofractionated involved-field radiation therapy (IFRT) omitting elective nodal irradiation (ENI) with concurrent chemotherapy for locally advanced non-small-cell lung cancer (NSCLC). Between July 2004 and July 2006, ten patients with locally advanced NSCLC were included in this study. One had stage IIIA and 9 had stage IIIB disease. The treatment consisted of IFRT in fractions of 2.5 Gy and weekly carboplatin (CBDCA)/paclitaxel (PTX). Hypofractionated IFRT with a median total dose of 65 Gy with median percent total lung volume exceeding 20 Gy (V20) of 20.2%, and a median of five courses of chemotherapy with weekly CBDCA (area under the curve, 1.5-2.0)/PTX (30-35 mg/m(2)) were given to all patients. The median survival time and the 1-, 2-, and 3-year overall survival rates were 29.5 months and 90.0%, 58.3%, and 43.8%, respectively. No elective nodal failure was encountered during the median follow up of 18.2 months. No acute or late toxicities of grade 3 or worse were observed. No in-field recurrence occurred in the group with a total dose of 67.5 Gy or more, but there was such recurrence in 83.3% of those in the group with less than 67.5 Gy. Hypofractionated IFRT with weekly CBDCA/PTX was a feasible treatment regimen. Hypofractionated IFRT with a total dose of 67.5 Gy or more could be a promising modality to improve the treatment results in patients with locally advanced NSCLC. |
|
言語 |
en |
出版者 |
|
|
出版者 |
Springer Tokyo |
言語 |
|
|
言語 |
eng |
資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
出版タイプ |
|
|
出版タイプ |
AO |
|
出版タイプResource |
http://purl.org/coar/version/c_b1a7d7d4d402bcce |
関連情報 |
|
|
|
関連名称 |
The original publication is available at www.springerlink.com |
関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1007/s10147-009-0889-0 |
関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
http://dx.doi.org/10.1007/s10147-009-0889-0 |
収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1341-9625 |
収録物識別子 |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA11086579 |
開始ページ |
|
|
開始ページ |
408 |
書誌情報 |
International Journal of Clinical Oncology
International Journal of Clinical Oncology
巻 14,
号 5,
p. 408-415,
発行日 2009-10-24
|
旧ID |
28880 |